-transparent.png){kind=logo}
Inhibition of duck hepatitis B virus replication by 2',3'-dideoxy-3'-fluoroguanosine in vitro and in vivo. 1996
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
Department of Medicine, University of Freiburg, Germany.
The antiviral activity of 2',3'-dideoxy-3'-fluoroguanosine (FdG) or its triphosphate was evaluated in the duck hepatitis B virus (DHBV) system in vitro and in vivo. In primary DHBV-infected hepatocytes FdG results in a dose-dependent inhibition of viral replication with a nearly complete inhibition at a concentration of 1 microM. Also in vivo, FdG treatment of DHBV-infected ducklings reduces DHBV DNA replication by more than 90%. These data demonstrate that FdG is a strong inhibitor of DHBV replication in vitro and in vivo.
Related Publications
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
January 1998,
Antiviral research,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
March 1996,
Journal of viral hepatitis,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
September 1991,
Acta virologica,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
January 2006,
Nucleosides, nucleotides & nucleic acids,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
November 1988,
Biochemical and biophysical research communications,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
October 1991,
Proceedings of the National Academy of Sciences of the United States of America,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
March 2006,
Antimicrobial agents and chemotherapy,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
July 1995,
Antimicrobial agents and chemotherapy,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
April 1992,
Biochemical pharmacology,
P Hafkemeyer, and
A Keppler-Hafkemeyer, and
M A al Haya, and
M von Janta-Lipinski, and
E Matthes, and
C Lehmann, and
W B Offensperger, and
S Offensperger, and
W Gerok, and
H E Blum
November 2015,
Experimental and therapeutic medicine,
